Patient With Three EGFR Mutations – Gradual Development of Resistance to Previous Targeted Treatment

Klinicka Onkologie - Czech Republic
doi 10.14735/amko201853
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Ambit Media, a.s.

Related search

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical Cancer Research
Cancer ResearchOncology
2015English

P1.13-15 Detection of EGFR Mutations in cfDNA and Development of Resistance

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Allosterically Targeting EGFR Drug-Resistance Gatekeeper Mutations

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy
OncologyPharmacology
2016English

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Resistance to Targeted Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2019English

Activation of the BMP-BMPR Pathway Conferred Resistance to EGFR-TKIs in Lung Squamous Cell Carcinoma Patients With EGFR Mutations

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2015English

Emergence of KRAS Mutations and Acquired Resistance to Anti-Egfr Therapy in Colorectal Cancer

Nature
Multidisciplinary
2012English

HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy